Pharmacopeia, Schering-Plough identify novel therapeutic candidate for metabolic disease

By Lisa Kerner

Erie, Pa., April 17 - Pharmacopeia said that a compound identified through its collaboration with Schering-Plough has been selected by Schering-Plough for preclinical development as a potential treatment for metabolic diseases.

"We are very pleased with Schering-Plough's decision to advance this compound which now becomes the sixth compound from our ongoing collaboration that is currently in development," president and chief executive officer Les Browne said in a company news release.

Under the collaboration, Schering-Plough is responsible for further development of the compounds.

Pharmacopeia will receive milestone payments for late-stage clinical trials and future royalties on sales of resulting products, the release stated.

The two companies have collaborated on the discovery of novel compounds for further research and development by Schering-Plough since 1994.

Currently Pharmacopeia has 12 partnered compounds in development with other pharmaceutical or biotechnology companies.

Located in Princeton, N.J., Pharmacopeia uses proprietary technologies to create novel therapeutics to address significant medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.